{'52WeekChange': 0.79192984,
 'SandP52WeekChange': None,
 'address1': 'Willemstraat 5',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 251.67,
 'askSize': 800,
 'averageDailyVolume10Day': 174187,
 'averageVolume': 198496,
 'averageVolume10days': 174187,
 'beta': 1.084883,
 'beta3Year': None,
 'bid': 251.1,
 'bidSize': 900,
 'bookValue': 11.953,
 'category': None,
 'circulatingSupply': None,
 'city': 'Breda',
 'companyOfficers': [],
 'country': 'Netherlands',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 257.89,
 'dayLow': 249.9,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': 10754680832,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 236.85,
 'fiftyTwoWeekHigh': 272.74,
 'fiftyTwoWeekLow': 103.75,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 42714052,
 'forwardEps': -12.11,
 'forwardPE': -20.753923,
 'fromCurrency': None,
 'fullTimeEmployees': 186,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'headSymbol': None,
 'heldPercentInsiders': 0,
 'heldPercentInstitutions': 0.56487,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/argenx.com',
 'longBusinessSummary': 'argenx SE, a clinical-stage biotechnology company, '
                        'focuses on developing antibody-based therapies for '
                        'the treatment of autoimmune diseases, hematology, and '
                        'cancer. It is developing its lead product candidate, '
                        'efgartigimod, for the treatment of patients with '
                        'myasthenia gravis in Phase 3; immune thrombocytopenia '
                        'in Phase 3; pemphigus vulgaris in Phase 2; chronic '
                        'inflammatory demyelinating polyneuropathy in Phase 2; '
                        'and ENHANZE SC in pre-clinical stages. The company is '
                        'also developing cusatuzumab in Phase 2 clinical stage '
                        'in hematological cancer indications; and preclinical '
                        'products, including ARGX-117 with therapeutic '
                        'potential in both orphan and large autoimmune '
                        'inflammatory diseases in and ARGX-118 for airway '
                        'inflammation. Its partnered product candidates '
                        'include ARGX-112 for treating skin inflammation and '
                        'ARGX-115 for cancer immunotherapy, which are in Phase '
                        '1 clinical stages; and ARGX-116 for the treatment of '
                        'dyslipidemia and ARGX-114 for treating fibrosis, '
                        'which are in preclinical stage. The company has '
                        'strategic partnership with AbbVie S.Ã\x80.R.L. and '
                        'LEO Pharma A/S; and collaboration agreement with '
                        'Cilag GmbH International, Staten Biotechnology B.V., '
                        'and Shire International GmbH. argenx SE was founded '
                        'in 2008 and is based in Breda, the Netherlands.',
 'longName': 'argenx SE',
 'market': 'us_market',
 'marketCap': 12261762048,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_62120637',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': None,
 'nextFiscalYearEnd': 1640908800,
 'open': 257.89,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': 0.4,
 'phone': '31 763 030 488',
 'previousClose': 255.35,
 'priceHint': 2,
 'priceToBook': 21.02652,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 257.89,
 'regularMarketDayLow': 249.9,
 'regularMarketOpen': 257.89,
 'regularMarketPreviousClose': 255.35,
 'regularMarketPrice': 257.89,
 'regularMarketVolume': 308310,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 46999800,
 'sharesPercentSharesOut': 0.0182,
 'sharesShort': 855217,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 853261,
 'shortName': 'argenx SE',
 'shortPercentOfFloat': None,
 'shortRatio': 2.36,
 'startDate': None,
 'strikePrice': None,
 'symbol': 'ARGX',
 'threeYearAverageReturn': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -1.725,
 'twoHundredDayAverage': 173.08676,
 'underlyingExchangeSymbol': None,
 'underlyingSymbol': None,
 'uuid': '96295c13-e973-32ba-ba5e-28b94bffe0bd',
 'volume': 308310,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.argenx.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '4811 AH'}